Search Results - Adewoye, Adeboye

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
    Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

    Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study by Kotasek, Dusan, Tebbutt, Niall, Desai, Jayesh, Welch, Stephen, Siu, Lillian L, McCoy, Sheryl, Sun, Yu-Nien, Johnson, Jessica, Adewoye, Adeboye H, Price, Timothy

    Published 2011
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Sickle Cell Leg Ulcers: Associations with Haemolysis and SNPs in Klotho, TEK and Genes of the TGF-β/BMP Pathway: —Sickle Cell Leg Ulcers, Genetics and Haemolysis—

    Sickle Cell Leg Ulcers: Associations with Haemolysis and SNPs in Klotho, TEK and Genes of the TGF-β/BMP Pathway: —Sickle Cell Leg Ulcers, Genetics and Haemolysis— by Nolan, Vikki G., Adewoye, Adeboye, Baldwin, Clinton, Wang, Ling, Ma, Qianli, Wyszynski, Diego F., Farrell, John J., Sebastiani, Paola, Farrer, Lindsay A., Steinberg, Martin H.

    Published 2006
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer

    Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer by De Boer, Richard H., Kotasek, Dusan, White, Shane, Koczwara, Bogda, Mainwaring, Paul, Chan, Arlene, Melara, Rebeca, Ye, Yining, Adewoye, Adeboye H., Sikorski, Robert, Kaufman, Peter A.

    Published 2012
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    Sickle Cell Vaso-occlusive Crisis Induces the Release of Circulating Serum Heat Shock Protein-70

    Sickle Cell Vaso-occlusive Crisis Induces the Release of Circulating Serum Heat Shock Protein-70 by Adewoye, Adeboye H., Klings, Elizabeth S., Farber, Harrison W., Palaima, Elizabeth, Bausero, Maria A., McMahon, Lillian, Odhiambo, Adam, Surinder, Safaya, Yoder, Mark, Steinberg, Martin H., Asea, Alexzander

    Published 2005
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

    Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies by Kater, Arnon P., Tonino, Sanne H., Spiering, Marjolein, Chamuleau, Martine E. D., Liu, Roberto, Adewoye, Adeboye Henry, Gao, Jie, Dreiling, Lyndah, Xin, Yan, Doorduijn, Jeanette K., Kersten, Marie José

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    Evaluation of the CLL-IPI in Relapsed and Refractory Chronic Lymphocytic Leukemia in Idelalisib Phase 3 Trials

    Evaluation of the CLL-IPI in Relapsed and Refractory Chronic Lymphocytic Leukemia in Idelalisib Phase 3 Trials by Soumerai, Jacob D., Ni, Ai, Xing, Guan, Huang, Julie, Furman, Richard R., Jones, Jeffrey, Sharman, Jeffrey P., Hallek, Michael, Adewoye, Adeboye H., Dubowy, Ronald, Dreiling, Lyndah, Zelenetz, Andrew D.

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    A network model to predict the risk of death in sickle cell disease

    A network model to predict the risk of death in sickle cell disease by Sebastiani, Paola, Nolan, Vikki G., Baldwin, Clinton T., Abad-Grau, Maria M., Wang, Ling, Adewoye, Adeboye H., McMahon, Lillian C., Farrer, Lindsay A., Taylor, James G., Kato, Gregory J., Gladwin, Mark T., Steinberg, Martin H.

    Published 2007
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial

    Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Contro... by Zelenetz, Andrew D., Barrientos, Jacqueline C., Brown, Jennifer R., Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S., Robak, Tadeusz, Sharman, Jeff P., Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H., Dreiling, Lyndah K., Kim, Yeonhee, Stilgenbauer, Stephan, Hillmen, Peter

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: